Circulating metabolites associated with incident myocardial infarction and stroke: A prospective cohort study of 90 438 participants

The relevance between circulating metabolites and vascular events remains controversial and comprehensive studies are lacking. We sought to investigate the prospective associations of plasma metabolomics with risks of incident stroke, ischemic stroke (IS), hemorrhagic stroke (HS), and myocardial infarction (MI). Within the UK Biobank cohort, 249 circulating metabolites were measured in 90 438 participants without baseline vascular diseases. Cox proportional hazards regressions were applied to estimate adjusted hazard ratios (HRs) for per 1 standard deviation increment in metabolites. The least absolute shrinkage and selection operator algorithm was used for selecting metabolite subsets. During a median of 9.0 years of follow‐up, we documented 833 incident stroke and 1256 MI cases. Lipid constituents, comprising cholesterol, cholesteryl esters, free cholesterol, phospholipids, and total lipids, in very low‐ (VLDL), intermediate‐ (IDL), and low‐density lipoprotein (LDL) particles were positively associated with MI risk (HR = 1.12 to 1.36; 95% CI = 1.06 to 1.44), while in high‐density lipoprotein (HDL) particles showed inverse associations (HR = 0.68 to 0.81; 95% CI = 0.63 to 0.87). Similar association pattern with MI was also observed for VLDL, IDL, LDL, and HDL particles themselves. In contrast, triglycerides within all lipoproteins, including most HDL particles, were positively associated with MI risk (HR = 1.14 to 1.28; 95% CI = 1.08 to 1.35) and, to a slightly lesser extent, with stroke and IS. Unsaturation of fatty acids and albumin were inversely associated with risks of stroke, IS, and MI. In contrast, the linear association for HS is absent. When combining multiple metabolites, the metabolite risk score captured a drastically elevated risk of all vascular events, about twice that of any single metabolite. Taken together, circulating metabolites showed remarkably widespread associations with incident MI, but substantially weakened associations with risks of stroke and its subtypes. Exhaustive metabolomics profiling may shed light on vascular risk prediction and, in turn, guide pertinent strategies of intervention and treatment.

[1]  E. Boerwinkle,et al.  Metabolomic Pattern Predicts Incident Coronary Heart Disease. , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[2]  E. Rimm,et al.  Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study , 2018, British Medical Journal.

[3]  R. Collins,et al.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.

[4]  L. Liang,et al.  Plasma lipidomic profiles and cardiovascular events in a randomized intervention trial with the Mediterranean diet. , 2017, The American journal of clinical nutrition.

[5]  Cathie Sudlow,et al.  UK Biobank: opportunities for cardiovascular research , 2017, European heart journal.

[6]  Debbie A Lawlor,et al.  Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies , 2017, American journal of epidemiology.

[7]  Xiaoke Yin,et al.  Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.

[8]  Brian A Ference,et al.  Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.

[9]  S. Humphries,et al.  Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.

[10]  J. Polak,et al.  Concentration of Smaller High‐Density Lipoprotein Particle (HDL‐P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA) , 2016, Journal of the American Heart Association.

[11]  R. Brook,et al.  Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.

[12]  Tom R. Gaunt,et al.  Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. , 2015, Circulation.

[13]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[14]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[15]  Tom R. Gaunt,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[16]  Xiang Wang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.

[17]  Jian Chen,et al.  Enhanced Neuroprotection by Local Intra-Arterial Infusion of Human Albumin Solution and Local Hypothermia , 2013, Stroke.

[18]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[19]  R. Collins,et al.  Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.

[20]  J. Mckenney,et al.  Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). , 2008, The American journal of cardiology.

[21]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[22]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[23]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[24]  A. Kontush,et al.  Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[25]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[26]  R. Busto,et al.  Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. , 2001, European journal of pharmacology.

[27]  P. Pattany,et al.  Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. , 1998, Stroke.

[28]  M D Ginsberg,et al.  Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. , 1997, Journal of neurosurgery.

[29]  B. J. Gersh Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .

[30]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[31]  C. Knoop,et al.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[32]  T. Asano,et al.  Beneficial effect of prolonged administration of albumin on ischemic cerebral edema and infarction after occlusion of middle cerebral artery in rats. , 1993, Neurosurgery.